Vaccination News Home Page subscribe Vaccination NewsLetter
http://ije.oupjournals.org/cgi/content/abstract/32/1/106
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
International Journal of Epidemiology 2003;32:106-115
© International
Epidemiological Association 2003
Infectious Diseases |
1 Department of Epidemiology Research, Danish
Epidemiology Science Centre, Statens Seruminstitut, Copenhagen, Denmark.
2 International Centre for Diarrhoeal Disease Research, Dhaka,
Bangladesh.
Peter Aaby, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark. E-mail: psb@sol.gtelecom.gw
Objective To examine whether the reduction in childhood mortality after immunization can be explained by the prevention of measles and its long-term effects.
Methods and Data We re-analysed an existing data set from Matlab, Bangladesh. During 1982–1985, measles immunization was used from 9 months of age in half of the study area, and the other half was used as an unvaccinated control area. A total of 8134 immunized children had been matched by age with 8134 non-immunized children; 578 children died during the follow-up period of 3 years. Using these data, we calculated the vaccine effectiveness against death (VED) controlling for significant factors in a matched analysis. In the absence of measles, there should be no difference in mortality between immunized, uninfected children and non-immunized, uninfected children. We therefore calculated VED after the exclusion of all measles cases in the survival analysis. To assess the long-term effects of measles, we compared survival of unvaccinated children after measles disease with children who had not yet contracted measles.
Results Prior to immunization and again after 1985, childhood
mortality rates were 10% lower in the area that had received
immunization. Though measles deaths only constituted 12.4% of the
non-accidental deaths, the VED controlling for significant factors
was 49% (95% CI: 38–58%). The vaccine was protective against measles
death throughout the study, but it also had a marked effect against
other causes of death, particularly diarrhoea and oedema. This effect
may have been particularly strong in the first 6 months after
immunization (VED = 74, 95% CI: 57–84%). The VED was only reduced
from 49% to 43% (95% CI: 31–54%) when measles cases were excluded in
the survival analysis. Controlling for background factors, mortality
among measles cases was increased during the acute phase (0–45
days) (mortality ratio [MR] = 17.35, 95% CI: 11.9–25.3) and in the
following 1
months (MR = 2.35, 95% CI: 0.95–5.84). However, post-measles cases
had significantly lower mortality than uninfected, non-immunized
children in the following 9 months (MR = 0.40, 95% CI: 0.16, 0.98).
Conclusions The non-randomized character of the original study and the possibility of uncontrolled confounding between the two areas prevent a precise estimate of the effectiveness of measles vaccine, but it is likely to have been substantial. Though there may have been some underreporting of cases of measles, the prevention of measles infection can only explain a limited part of the observed impact of measles immunization in Bangladesh. Furthermore, mortality may be reduced after the acute phase of measles infection. The observations from Bangladesh are consistent with recent research from Africa suggesting that measles immunization may have non-specific beneficial effects on survival.
Keywords Measles, measles immunization, non-specific effects of vaccination, post measles mortality
Accepted 23 July 2002
This article has been cited by other articles:
![]() |
P. E. Fine Commentary: Non-specific effects of measles vaccine--more grist for the mill Int. J. Epidemiol., February 1, 2003; 32(1): 116 - 117. [Full Text] |
||||
|
|||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Copyright © 2003 International Epidemiological Association.
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.